INTRODUCTION
============

Pneumonia is the second most common cause of in-hospital infection. Pneumonia is very common in the intensive care unit (ICU) setting and can be fatal. The incidence of pneumonia is about 17% in the medical ICU \[[@b1-kjim-30-6-829]\] but can be 6 to 20 times higher in mechanically ventilated patients \[[@b2-kjim-30-6-829]\]. The mortality rate of hospital-acquired pneumonia (HAP) depends on the clinical situation, but can range from 20% to 50% \[[@b3-kjim-30-6-829],[@b4-kjim-30-6-829]\]. Determining the prognosis of pneumonia is important for anticipating the disease course and establishing a proper management plan.

The causative micro-organism can influence the clinical presentation, outcome of antibiotic therapy, and prognosis in patients with pneumonia. However, whether the causative organism influences the clinical course of pneumonia in the ICU is controversial. Identifying a pathogen by culture can be a poor prognostic factor \[[@b5-kjim-30-6-829]\], and infection with multidrug-resistant (MDR) pathogens such as *Acinetobacter baumannii* or methicillin-resistant *Staphylococcus aureusi* (MRSA) is a risk factor for hospital mortality \[[@b6-kjim-30-6-829]-[@b8-kjim-30-6-829]\]. However, one study reported that the pathogen classification or the existence of MDR pathogens does not affect the mortality rate after adjusting for the effect of antibiotics \[[@b9-kjim-30-6-829]\]. Although one study has reported the epidemiology and causative micro-organisms of pneumonia in Korea \[[@b10-kjim-30-6-829]\], the prognosis of pneumonia according to the causative micro-organism in the ICU is not well known. Thus, in this study, we elucidated the clinical manifestations and prognosis of patients with pneumonia according to the causative pathogen in the medical ICU.

METHODS
=======

Study design and participants
-----------------------------

A retrospective observational study was performed in the medical ICU of the Seoul National University Hospital between January 2011 and August 2011. We included patients with pneumonia treated in the medical ICU. Patients were enrolled if they had pneumonia on admission or developed pneumonia during their ICU stay. A total of 242 patients were admitted and treated in the medical ICU over the study period; in addition, data from 102 patients with pneumonia were analyzed retrospectively.

Pneumonia was clinically classified based on the American Thoracic Society/Infectious Disease Society of America guidelines \[[@b11-kjim-30-6-829],[@b12-kjim-30-6-829]\]. According to these guidelines, healthcare-associated pneumonia (HCAP) was defined as pneumonia in any patient admitted to an acute care hospital for ≥ 2 days within 90 days of the infection; who resided in a nursing home or long-term care facility; who received recent intravenous antibiotic therapy, chemotherapy, or wound care within 30 days of onset of the current infection; or who attended a hospital or hemodialysis clinic within 30 days. HAP was defined as pneumonia that developed ≥ 48 hours after admission. Community-acquired pneumonia (CAP) was defined as pneumonia that did not meet any of the HCAP and HAP criteria.

The causative organisms were considered to be micro-organisms that had been isolated from specimens, including blood, bronchoalveolar lavage fluid, bronchial wash, and pleural effusion, and which grew to greater than a threshold concentration in quantitative cultures. Specimens obtained by endotracheal aspiration or in sputum expectorant were evaluated as appropriate using counts of white blood cells and epithelial cells, and the micro-organisms identified were considered the causative pathogen. Growth below the threshold was considered to be caused by colonization or contamination. *Legionella* and *Streptococcus* urinary antigen tests, viral polymerase chain reaction, and antigen tests were also used to identify the pathogens. Pathogens may have been confirmed in additional samples after a patient developed pneumonia, but a secondary infection due to a hospital- or ICU-acquired pathogen was ruled out. Specimens sampled within 3 days after a patient developed pneumonia were considered significant.

Empirical antibiotic regimens to treat pneumonia were reviewed, and their response and relevance to subsequent changes in the antibiotic regimen were analyzed. The initial empirical antibiotic regimen was administered according to the American Thoracic Society/Infectious Disease Society of America guidelines \[[@b11-kjim-30-6-829],[@b12-kjim-30-6-829]\]. Initial non-responders to empirical antibiotics were defined as cases in which the initial antibiotic was changed due to expansion or a switch in the antibiotic spectrum due to persistence or worsening of the clinical course within 1 week after developing pneumonia. This did not include cases in which empirical antibiotics were changed to the targeted regimen based on drug susceptibility in clinically improving patients.

We analyzed ICU mortality, duration of ICU stay, duration of mechanical ventilation, frequency of re-intubation, and frequency of tracheostomy as clinical outcomes of pneumonia. These outcomes were compared between patients with CAP, HCAP, and HAP.

This retrospective data collection was approved by the Institutional Review Board of Seoul National University (IRB no: H-1208-150-424) and was performed in accordance with the Declaration of Helsinki.

Statistical analysis
--------------------

Data are presented as means and standard deviations for continuous variables and as numbers (percentages) for categorical variables. We analyzed baseline characteristics, clinical outcomes, and prognoses according to specific pathogens using the Kruskal-Wallis test. We used the Mann-Whitney test to compare data for prognosis according to whether a pathogen or MDR pathogen was identified. Associations between prognostic factors and survival rate were investigated using the Cox proportional-hazard analysis after adjusting for age, sex, Acute Physiology and Chronic Health Evaluation (APACHE) II score \[[@b13-kjim-30-6-829]\], Sequential Organ Failure Assessment (SOFA) score \[[@b14-kjim-30-6-829]\], Charlson comorbidity index \[[@b15-kjim-30-6-829]\], pneumonia severity index \[[@b16-kjim-30-6-829]\], the identification of the pathogen or MDR pathogen, and the pneumonia classification. Likelihood ratio tests were used to examine the goodness of fit of the model, and no lack of fit was found. Adjusted odd ratios (aOR) are presented with 95% confidence intervals (CIs). A p \< 0.05 was considered significant. Data were analyzed using SPSS version 18 (SPSS Inc., Chicago, IL, USA).

RESULTS
=======

Baseline characteristics and clinical outcomes of the patients
--------------------------------------------------------------

During the study period, 242 patients were admitted to the ICU; 102 had pneumonia, and all were eligible for this study. The study population was comprised of 20 patients (19.6%) with CAP, 26 (25.5%) with HCAP, and 56 (54.9%) with HAP.

The baseline characteristics and clinical outcomes of the patients treated for pneumonia in the ICU are presented in [Table 1](#t1-kjim-30-6-829){ref-type="table"}. Mean age of the entire population was 64.1 ± 14.3 years, and 75.5% were men. No significant differences were found between the CAP, HCAP, and HAP groups for age, sex distribution, or severity as evaluated by the APACHE II score and the SOFA score. However, the Charlson comorbidity index and pneumonia severity index scores were significantly higher in the HCAP and HAP groups than in the CAP group; the scores did not differ between the HCAP and HAP groups.

The causative pneumonia pathogens were identified in 50 patients (49.0%). No significant differences in baseline characteristics were observed according to the pathogens identified except for a history of solid tumor within 5 years and the presence of a MDR pathogen.

Distribution of causative pathogens and clinical outcomes
---------------------------------------------------------

Among 50 cases in which a pathogen was identified, sputum (24, 48%), blood (17, 34%), endotracheal aspirate (12, 24%), bronchoalveolar lavage (4, 8%), serology (4, 8%), and bronchial wash (2, 4%) were the specimens in which pathogens were confirmed. The pathogens causing pneumonia were identified in nine patients (45%) with CAP, in 11 (42.3%) with HCAP, and in 30 (53.6%) with HAP. No significant difference in the incidence of pathogens was observed among the pneumonia types after adjusting for culture frequency. The incidence of pneumonia with a MDR pathogen was 22 patients (21.6%) in the entire population. The incidence was significantly higher in the HAP group than in the HCAP and CAP groups (HAP, 32.1%; HCAP, 11.5%; CAP, 5.0%; *p* = 0.015), but was not different between the CAP and HCAP groups. The MDR micro-organisms were: carbapenem-resistant *A. baumannii*, MRSA, coagulase-negative *Staphylococcus*, vancomycin-resistant enterococci, extended-spectrum b-lactamase-producing *Escherichia coli, Klebsiella*, and MDR *Pseudomonas* species.

[Table 2](#t2-kjim-30-6-829){ref-type="table"} shows the distribution of specific pathogens and the respective prognoses. *S. aureus* was the most frequently isolated pathogen among all patients in all groups (10, 20%). *Pseudomonas* species were detected in eight patients (16%), *Klebsiella pneumoniae* in seven (14%), and *A. baumannii* in six (12%). No significant difference was observed in the clinical outcomes between specific pathogens.

Regimen and response to empirical antibiotic treatment
------------------------------------------------------

The empirical antibiotics and their responses are shown in [Table 3](#t3-kjim-30-6-829){ref-type="table"}. The most commonly used antibiotics as an empirical regimen, including combination therapy, were β-lactam/β-lactamase inhibitors (62, 60.8%), followed by quinolones (57, 55.9%). About 58% of the patients responded initially to the empirical antibiotic regimen. Appropriate antibiotics were initially used in 60% of cases when a retrospective review was performed considering pathogen drug susceptibility and the antibiotic spectrum in cases in which the pathogen was identified. In these cases, a subsequent change to the targeted antibiotic occurred in 56% of cases, and most (89.3%) were appropriate considering the drug susceptibility of the pathogen.

Clinical outcomes according to identification of the causative organism and pneumonia classification
----------------------------------------------------------------------------------------------------

The prognoses of pneumonia based on identifying the pathogens are shown in [Table 4](#t4-kjim-30-6-829){ref-type="table"}. The ICU mortality rate was 47.1% in the entire study population, and did not differ according to whether the pathogen was identified (unidentified pathogen 46.2% vs. identified pathogen 48.0%, *p* = 0.853). Other clinical outcomes such as duration of ICU stay, need for and duration of mechanical ventilation, and frequencies of re-intubation and tracheostomy were different based on whether the pathogen was identified. These results were consistent with cases in which MDR pathogens were identified.

A subgroup analysis was performed according to pneumonia type, and the clinical outcomes did not differ significantly between the groups.

Prognostic factors for mortality
--------------------------------

A Cox proportional-hazard analysis was performed to evaluate the relative risk of ICU mortality caused by pneumonia, and the data are presented in [Table 5](#t5-kjim-30-6-829){ref-type="table"}. The ICU mortality rate was significantly higher in the group with higher APACHE II and SOFA scores in both univariate and multivariate analyses (\[APACHE II score: aOR, 1.07; 95% CI, 1.03 to 1.11\]; \[SOFA score: aOR, 1.26; 95% CI, 1.14 to 1.38\]). Age was also a significant prognostic factor for ICU mortality in the multivariate analysis (aOR, 1.04; 95% CI, 1.01 to 1.07). The pneumonia severity index was significantly associated with ICU mortality in the univariate analysis, but significance was lost after adjustment. Age, sex, the Charlson comorbidity index, identification of the pathogen or MDR pathogen, initial responder to empirical antibiotic therapy, and pneumonia classification were not significant prognostic indicators in the ICU mortality evaluation.

DISCUSSION
==========

In our study, patients with HCAP and HAP had significantly more severe comorbidity and pneumonia than those of patients with CAP, but the number of pathogens identified did not differ between the pneumonia types. More MDR pathogens were identified in the HAP than those in the CAP and HCAP groups. However, the influence of the pathogen or MDR pathogen identified on the clinical outcomes, such as ICU mortality rate, ICU duration, duration of mechanical ventilation, and frequencies of re-intubation and tracheostomy, was not significant in the entire population or in subgroups according to the pneumonia classification.

It is controversial whether the pneumonia prognosis differs according to whether the pathogen is identified. In previous studies on the pneumonia prognosis, the severities of underlying disease and comorbidities were evaluated as important prognostic factors. Some HCAP and HAP studies have shown that age, multi-organ dysfunction, septic shock, the Charlson comorbidity index, and SOFA and APACHE II scores are significant prognostic factors for patients with pneumonia \[[@b6-kjim-30-6-829],[@b9-kjim-30-6-829],[@b17-kjim-30-6-829]\]. Other studies of patients with severe CAP who required mechanical ventilation or ICU admission reported acute renal failure, septic shock, and the Simplified Acute Physiology Score II as significant prognostic factors \[[@b18-kjim-30-6-829],[@b19-kjim-30-6-829]\].

In this study, the evaluation of ICU mortality according to the prognostic factors of pneumonia showed that higher APACHE II and SOFA scores were significantly associated with a lower survival rate, but the identification status and the microbe causative of pneumonia were not. This result suggests that the severity of pneumonia or underlying disease may be a more important prognostic factor than microbial etiology, and these data coincide with those of a recent prospective cohort study in Spain, which showed that comorbidities are a stronger determinant of mortality than microbial etiology in a comparison between CAP and HCAP \[[@b20-kjim-30-6-829]\].

Several limitations in this study should be mentioned. This study was performed retrospectively in a single tertiary referral hospital; thus, there may have been selection bias because several of the patients enrolled had severe or advanced disease and some patients may have been immunocompromised. The small study population may have limited the statistical power and subgroup analysis. In the pathogen evaluation, MRSA and gram-negative rods may be more easily detected because they are well seen in gram-stained specimens and cultures than anaerobes and viruses. Finally, the initial antibiotic therapy and responses were not analyzed in this study.

In conclusion, we found that neither identifying the causative micro-organism nor the existence of a MDR pathogen was associated with the clinical outcomes of pneumonia, including ICU mortality. The severity of the underlying disease or pneumonia itself may be a significant prognostic indicator, regardless of whether the causative micro-organism is identified or if the pneumonia is classified.

KEY MESSAGE
===========

1\. The causative pathogen was identified in 49.0% of patients with pneumonia treated in the medical intensive care unit (ICU); 21.6% of patients had a multidrug-resistant pathogen.

2\. In the clinical outcomes of pneumonia including ICU mortality, the severity of the underlying disease or pneumonia itself may be a significant prognostic indicator, regardless of the causative micro-organism or the pneumonia classification.
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###### 

Baseline characteristics of patients with pneumonia treated in the intensive care unit

  Characteristic                     Overall (n = 102)   Pathogen not identified (n = 52)   Pathogen identified (n = 50)   *p* value
  ---------------------------------- ------------------- ---------------------------------- ------------------------------ -----------
  Age, yr                            64.1 ± 14.3         66.0 ± 11.5                        62.1 ± 16.5                    0.410
  Male sex                           77 (75.5)           43 (82.7)                          34 (68)                        0.086
  APACHE II score                    26.1 ± 9.4          26.0 ± 9.4                         26.2 ± 9.5                     0.815
  SOFA score                         8.9 ± 4.4           8.5 ± 3.7                          9.4 ± 5.1                      0.541
  Pneumonia severity index           142.7 ± 39.7        142.3 ± 41.6                       143.1 ± 38.1                   0.723
  Charlson comorbidity index         3.7 ± 2.5           3.7 ± 2.7                          3.6 ± 2.4                      0.837
  Comorbidity                                                                                                              
   Chronic lung disease              29 (28.4)           17 (32.7)                          12 (24)                        0.333
   Chronic heart disease             8 (7.8)             3 (5.8)                            5 (10)                         0.429
   Chronic liver disease             17 (16.7)           6 (11.5)                           11 (22)                        0.158
   Chronic renal disease             15 (14.7)           5 (9.6)                            10 (20)                        0.141
   Solid tumor                       42 (41.2)           28 (53.8)                          14 (28)                        0.008
   Diabetes mellitus                 32 (31.4)           12 (23.1)                          20 (40)                        0.067
   Hematologic malignancy            18 (17.6)           6 (11.5)                           12 (24)                        0.101
  Pneumonia type                                                                                                           
   Community-acquired pneumonia      20 (19.6)           11 (21.2)                          9 (18)                         0.690
   Healthcare-associated pneumonia   26 (25.5)           15 (28.8)                          11 (22)                        0.430
   Hospital-acquired pneumonia       56 (54.9)           26 (50)                            30 (60)                        0.313
  MDR pathogen                       22 (21.6)           0                                  22 (44)                        \< 0.001

Values are presented as mean ± SD or number (%).

APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; MDR, multidrug-resistant.

###### 

Microetiological diagnoses and prognoses of pneumonia when the causative pathogen was identified (n = 50)

  Variable                                 Frequency   MDR proportion   ICU mortality, %   ICU LOS, day   MV duration, day
  ---------------------------------------- ----------- ---------------- ------------------ -------------- ------------------
  Gram-positive bacteria                                                                                  
   *Staphylococcus aureus*                 10 (20)     6 (60)           4 (40)             13.0 ± 8.8     7.7 ± 7.4
   *Streptococcus pneumoniae*              3 (6)       0                1 (33.3)           40 ± 17.6      22.7 ± 26.7
   *Enterococcus faecium*                  1 (2)       1 (100)          1                  5              5
  Gram-negative bacteria                                                                                  
   Enterobacteriaceae                                                                                     
    *Klebsiella pneumoniae*                7 (14)      2 (28.6)         4 (57.1)           7.4 ± 5.5      2.6 ± 3.0
    *Acinetobacter baumannii*              6 (12)      5 (83.3)         3 (50)             12.7 ± 15.5    12.8 ± 15.5
    *Escherichia coli*                     3 (6)       2 (66.7)         1 (33.3)           11.0 ± 10.1    3.3 ± 4.9
    *Enterobacter aerogenes*               2 (4)       1 (50)           0                  13.0 ± 17.0    12.5 ± 17.7
   Nonfermentative gram-negative bacilli                                                                  
    *Pseudomonas* species                  8 (16)      5 (62.5)         3 (37.5)           13.1 ± 8.0     5.9 ± 8.0
    *Stenotrophomonas maltophilia*         2 (4)       2 (100)          2 (100)            4.0 ± 1.4      3.5 ± 2.1
  Mycobacterium                                                                                           
   *Mycobacterium tuberculosis*            1 (2)       0                0                  52             9
   Non-tuberculosis *Mycobacterium*        1 (2)       0                1 (100)            1              0
  Fungi                                                                                                   
   *Aspergillus* species                   5 (10)      0                3 (60)             23.2 ± 29.8    19.0 ± 29.1
  Virus                                                                                                   
   *Cytomegalovirus*                       4 (8)       0                2 (50)             20.5 ± 14.6    12.5 ± 8.2
  Atypical pathogen                                                                                       
   *Pneumocystis jiroveci*                 2 (2.0)     0                1 (50)             14.5 ± 6.4     13.5 ± 7.8
   *Mycoplasma species*                    1 (1.0)     0                1 (100)            15             15

Values are presented as number (%) or mean ± SD.

MDR, multidrug-resistant; ICU, intensive care unit; LOS, length of stay; MV, mechanical ventilation.

###### 

Empirical antibiotic regimen and response (n = 102)

  Variable                                                           No. (%)
  ------------------------------------------------------------------ -----------
  Empirical antibiotic treatment                                     
   β-Lactam/β-lactamase inhibitor                                    62 (60.8)
   Quinolone                                                         57 (55.9)
   Carbapenem                                                        20 (19.6)
   Vancomycin                                                        19 (18.6)
   Cephalosporin                                                     15 (14.7)
   Trimethoprim/sulfamethoxazole                                     14 (13.7)
   Antifungal agents                                                 10 (9.8)
   Antiviral agents                                                  5 (4.9)
   Macrolides                                                        5 (4.9)
   Colistin                                                          3 (2.9)
  Initial responder to empirical antibiotic therapy                  59 (57.8)
  Antibiotics response in cases with identified pathogens (n = 50)   
   Initially appropriate antibiotics                                 30 (60)
   Subsequent change to targeted antibiotics                         28 (56)
   Appropriate change according to drug susceptibility               25 (89.3)

###### 

Clinical outcomes and prognoses of pneumonia according to whether the pathogen was identified

  Variable                   Pathogens     MDR pathogens                                      
  -------------------------- ------------- --------------- ------- ------------- ------------ -------
  Overall (n = 102)          52            50                      80            22           
   ICU mortality             24 (46.2)     24 (48)         0.853   38 (47.5)     10 (45.5)    0.865
   ICU length of stay, day   19.0 ± 26.8   15.4 ± 15.4     0.176   18.7 ± 24.3   11.8 ± 7.6   0.305
   MV duration, day          15.5 ± 27.3   10.1 ± 13.7     0.060   14.4 ± 24.1   7.0 ± 7.1    0.062
   Re-intubation             9 (17.3)      5 (10)          0.286   13 (16.3)     1 (4.5)      0.189
   Tracheostomy              13 (25)       11 (22)         0.722   18 (22.5)     6 (27.3)     0.777
  CAP group (n = 20)         11            9                       19            1            
   ICU mortality             2 (18.2)      5 (55.6)        0.160   6 (31.6)      1 (100)      0.350
   ICU length of stay, day   14.9 ± 10.1   15.9 ± 16.0     0.909   15.4 ± 13.1   15           0.794
   MV duration, day          11.5 ± 10.4   7.3 ± 7.7       0.340   9.3 ± 9.4     15           0.257
   Re-intubation             3 (27.3)      2 (22.2)        1.000   5 (26.3)      0            1.000
   Tracheostomy              4 (36.4)      0               0.094   4 (21.1)      0            1.000
  HCAP group (n = 26)        15            11                      23            3            
   ICU mortality             7 (46.7)      2 (18.2)        0.217   9 (39.1)      0            0.294
   ICU length of stay, day   15.5 ± 8.3    18.0 ± 18.6     0.612   17.4 ± 13.9   9.7 ± 6.7    0.377
   MV duration, day          11.9 ± 7.8    11.4 ± 14.9     0.275   12.6 ± 11.4   5.0 ± 5.6    0.137
   Re-intubation             3 (20)        1 (9.1)         0.614   4 (17.4)      0            1.000
   Tracheostomy              1 (6.7)       2 (18.2)        0.556   3 (13)        0            1.000
  HAP group (n = 56)         26            30                      38            18           
   ICU mortality             15 (57.7)     17 (56.7)       0.939   23 (60.5)     9 (50)       0.461
   ICU length of stay, day   22.7 ± 36.8   14.2 ± 14.5     0.277   21.1 ± 32.4   12.0 ± 8.1   0.493
   MV duration, day          19.2 ± 37.5   10.5 ± 14.8     0.226   18.1 ± 33.0   6.9 ± 7.3    0.106
   Re-intubation             3 (11.5)      2 (6.7)         0.655   4 (10.5)      1 (5.6)      0.662
   Tracheostomy              8 (30.8)      9 (30)          0.951   11 (28.9)     6 (33.3)     0.741

Values are presented as number (%) or mean ± SD.

MDR, multidrug-resistant; ICU, intensive care unit; MV, mechanical ventilation; CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia; HAP, hospital-acquired pneumonia.

###### 

Risk of intensive care unit mortality according to prognostic factors in the entire population

  Prognostic factor                                   Univariate          Adjusted                        
  --------------------------------------------------- ------------------- ---------- -------------------- ----------
  Age, yr                                             1.01 (0.99--1.02)   0.595      1.04 (1.01--1.07)    0.003
  Male sex                                            0.63 (0.32--1.22)   0.168      0.59 (0.28--1.25)    0.169
  APACHE II score                                     1.06 (1.03--1.09)   \< 0.001   1.08 (1.04--1.12)    \< 0.001
  SOFA score                                          1.20 (1.12--1.28)   \< 0.001   1.31 (1.18--1.45)    \< 0.001
  Charlson comorbidity index                          1.03 (0.92--1.14)   0.658      1.14 (0.99--1.32)    0.066
  Pneumonia severity index                            1.01 (1.00--1.02)   0.027      0.998 (0.99--1.01)   0.680
  Identified pathogen                                 1.21 (0.68--2.14)   0.523      1.86 (0.83--4.17)    0.131
  Multidrug-resistant pathogen                        1.39 (0.68--2.84)   0.365      0.52 (0.21--1.29)    0.159
  Initial responder to empirical antibiotic therapy   1.03 (0.58--1.83)   0.924      0.62 (0.33--1.15)    0.131
  Pneumonia classification                                                                                
   Community-acquired pneumonia                       1 (reference)                  1 (reference)        
   Healthcare-associated pneumonia                    0.92 (0.34--2.48)   0.872      0.35 (0.10--1.22)    0.100
   Hospital-acquired pneumonia                        1.56 (0.69--3.55)   0.289      1.62 (0.53--4.91)    0.395

OR, odds ratio; CI, confidence interval; APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment.
